RESI Toronto 2018 Sponsors and Exhibitors List

~ Next Phase Admin ~ Leave a comment

By Sean Tran, Business Development Manager, LSN

The Life Science Nation team is pleased to announce the sponsors and exhibitors for our third RESI conference in Toronto. Attracting over 600 attendees, sponsors and exhibitors will be in the spotlight of our exhibition hall, standing out as leaders in the life science industry.

Twenty companies will participate in the Exhibition, displaying their products and services. The array of offerings from these exhibitors will give attending companies a chance to meet valuable partners to help move their technologies forward in development.

Exhibitors

Title Sponsors

Gold Sponsors

Silver Sponsors

Bronze Sponsors

MaRS Supporters

Media Sponsors

 

Thank you for your support of the conference and your commitment to the continual advancement of the healthcare industry.

Hot Investor Mandate 1: Large VC Firm Focused on Data-Driven Life Science Technologies, from Devices to Computational Drug Discovery

~ Next Phase Admin ~ Leave a comment

A venture capital firm with offices in California backs entrepreneurs applying deep and differentiated technology to transform giant industries. The firm focuses on seed and series A investments and has raised multiple funds to date, with over $1B AUM. The firm usually makes seed investments in the range of $250K – $1M and venture-stage investments from $1M-$4M and may use both convertible notes or straight equity. The firm may lead or co-invest in a syndicate and looks to add unique value to entrepreneurs with a strong Equity Partner network, operational experience and technical background.

The firm invests in several verticals and is focused on deep technologies such as AI, advanced materials, quantum computing, etc. In the healthcare space, the firm is focused on the entire continuum including computational drug discovery, AI-driven diagnostics, better/faster clinical trials and technologies used by payers and providers to better understand and manage risk and drive better outcomes. The common theme is that the startup’s underlying technology be novel and data-driven. The firm is also interested in synthetic biology. The firm does not invest in biopharma or traditional medical devices/diagnostics with a standard regulatory pathway.

The firm requires that startups have some type of proof-of concept and traction. The firm prefers experienced/proven management teams and entrepreneurs that are introduced through the firm’s network. The firm typically seeks a board seat when leading an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Healthcare-Focused VC and PE Fund Invests in North American Companies in Therapeutics, Medical Devices, Digital Health and Services

~ Next Phase Admin ~ Leave a comment

A private equity and venture fund is currently focused on health care investments such as therapeutics, medical devices, health care services, and digital health companies. The firm likes to invest early, generally seed-series A, as one of the earliest investors, and be involved throughout the life of the company, helping it grow and develop. The firm invests primarily in companies in North America. The firm will generally invest $250,000-$2M in the initial investment, with the potential for continuing funding. Because the firm prefers to play an active role in their portfolio companies, the firm will only invest in a limited number of companies at any given time.

The firm primarily invests in therapeutics and medical devices. Because the firm prefers to invest early, they look at companies that are still pre-clinical/in development and, for devices, will consider PMA as well as 510k devices. The firm is indication agnostic, focusing on technologies that inspire their passion. The firm will consider investing in technologies related to orphan diseases.

The firm has no specific management team requirements. Due to the firm’s active role in their portfolio companies, the firm does like to take a board seat following the investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Technology Firm Establishes New Venture Fund for Investing in Early-Stage Digital Health Companies Globally

~ Next Phase Admin ~ Leave a comment

An operating group of a global public technology firm with an $18B market cap. The group began its venture portfolio in 2018 with investments in B-to-B software companies targeted at specific vertical markets such as healthcare. The fund invests $0.5M – 1M per company and is seeking companies raising seed to Series B rounds. The company is seeking 5 – 10 new investments to build their initial portfolio. The company prefers companies based in Canada, though as the parent firm is located in the US, UK, EU, and AU, the fund is open to invest globally.

The company is seeking healthcare IT, and they are particularly investing in technologies with a software component. The firm prefers commercial-stage companies, though is open to looking at clinical-stage companies as well. The company is indication agnostic.

The company will help companies fill management team positions, if necessary. The company prefers companies that are generating $100K – 3M in annual revenue.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: USA and China-Based Biotech Company Seeks to Invest in Life Science Companies, with Focus on Cell/Gene Therapies, Antibodies, Synthetic Biology, etc.

~ Next Phase Admin ~ Leave a comment

A public biotech company with headquarters in USA and China is actively seeking for investment, partnering and acquisition opportunities to expand the company’s business in multiple areas. The firm usually invests as a strategic investor in as early as seed rounds. Typical allocations are $1-5 M.

The firm’s sectors of focus are cell and gene therapies, antibody therapeutics, life science tools, drug discovery technologies, synthetic biology technologies and industrial enzyme products.

The firm may seek a board seat depending upon size of investment. The firm is open to working with all stages of management teams and may lead or co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

RESI Toronto Innovation Challenge Finalists Announced

~ Next Phase Admin ~ Leave a comment

By Cole Bunn, Director of Research, LSN

cole-wp

We are excited to showcase the top 30 RESI Innovation Challenge startup applicants, who will be taking part in the poster presentation showcase at the third annual RESI conference held in Toronto, as a part of the Toronto Health Innovation Week. These handpicked companies represent the key sectors of the healthcare space including therapeutics, medical devices, diagnostics and digital health, and were selected based on their scientific/technical merit and commercial viability.

The Innovation Challenge companies will compete for each attendee’s RESI Cash tokens throughout the day, which serves as a vote of their potential. The top 3 companies will win additional RESI tickets to events of their choosing and a feature in the LSN newsletter (20,000 readership), giving them access to hundreds of additional investors and ultimately enhancing their likelihood of securing an investment. Make sure to visit the exhibition hall to meet the RESI innovators and “invest” in your favorites!

Therapeutics

MedTech Device

Diagnostics

Digital Health

RESI on MaRS Panel Announcement: Venture Philanthropy

~ Next Phase Admin ~ Leave a comment

By James Huang, Research Analyst, LSN

james-wp

RESI endeavors to bring a diverse pool of investors to each of our events for early stage life science companies. Among them are venture philanthropic foundations whose profound expertise within their targeted disease areas makes them great resources for any entrepreneur looking to work within their areas of expertise. Additionally, venture philanthropic investors tend to focus on assets at an earlier stage than typical VCs, with the aim of helping new treatments traverse the infamous “Valley of Death.”

LSN is pleased to announce a panel of five venture philanthropic investors for the upcoming RESI on MaRS this April 10th in Toronto. In this panel, these investors will explain their unique strategies and expertise, and entrepreneurs can learn how to find and work with a venture philanthropy investor in their domain. RESI attendees will have the exclusive opportunity to hear from: